Drugs Made In America Acquisition Corp. (DMAA) company profile
Close on Nov 13, 2026Market cap $264.62MP/E –Yield –
About Drugs Made In America Acquisition
Blank Checks, SIC 6770
Drugs Made In America Acquisition Corp. is a blank check shell company formed to complete a merger, share exchange, asset acquisition, reorganization, or similar corporate transaction with one or more operating businesses. The company does not market commercial products, provide commercial services, or generate operational revenue. It currently maintains no distinct business operating segments and serves no direct commercial customers. Instead, the firm focuses its acquisition efforts on enterprises operating in artificial intelligence, pharmaceuticals, or other innovation-oriented industries that require developmental support.
The company is incorporated in the Cayman Islands and maintains its principal executive offices in New York, New York. As a shell entity without active commercial operations, it owns no retail stores, production plants, or regional physical facilities. Its business search primarily targets prospective operating entities located within the United States.
Summary of the business section of Drugs Made In America Acquisition's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Drugs Made In America Acquisition Corp.
- Headquarters
- New York, NY
- Address
- 420 Lexington Avenue, Suite 1402 10170
- Phone
- (646) 726-7074
- Employees
- 10, Dec 31, 2024
- Industry
- Blank Checks
- Fiscal year ends
- December 31
- Auditor
- MaloneBailey, LLP, Houston, Texas
Stock & identifiers
- Ticker
- DMAA
- Other tickers
- DMAAR, DMAAU
- Exchange
- Nasdaq
- IPO date
- Jan 29, 2025
- Shares outstanding
- 24M, Aug 14, 2026
- Public float
- $234.60M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2028614
- CUSIP
- G2847J104
- FIGI
- BBG01RQ5FQV1
- Share class FIGI
- BBG01RQ5FRS3
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lynn Stockwell | CEO and Exe. Chair of Board, Director | 4,188,780 |
| Glenn C. Worman | CFO | 100,000 |
| Catherine Do | Director | 100,000 |
| Myron W. Shulgan | Director | 100,000 |
| Sridhar G. Prasad | Director | 100,000 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Jan 29, 2025
- Offer price
- $10.00
- Securities offered
- 20,000,000
- Gross proceeds
- $200.00M
- First trading day
- Jan 28, 2025
- First-day close
- $10.000.0%
- Lock-up ends (est.)
- Jul 27, 2025
“Each unit has an offering price of $10.00 and consists of one ordinary share and one right to receive one -eighth (1/8) of an ordinary share upon the consummation of an initial business combination, as described in more detail below, which we refer to throughout this prospectus as the “public rights”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 1, 2026 | Late filing | Notification of late filing |
| Nov 17, 2025 | Late filing | Notification of late filing |
| May 15, 2025 | Late filing | Notification of late filing |
| Jan 29, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 7, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?